RGD Peptides

Handbook of Biologically Active Peptides

Volumn , Issue , 2013, Pages 705-713

  Siemion, Ignacy Z ^a   Kluczyk, Alicja ^a   Cebrat, Marek ^a  

^a UNIVERSITY OF WROC AW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884951512     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385095-9.00095-6     Document Type: Chapter

References (35)

1. Aguzzi M.S., Fortugno P., Giampietri C., Ragone G., Capogrossi M.C., Facchiano A. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer 2011, 9:84-94.
2. Anderson M.E., Siahaan T.J. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 2003, 24:487-501.
3. Arnaout M.A., Goodman S.L., Xiong J.P. Coming to grips with integrin binding to ligands. Curr Opin Cell Biol 2002, 14:641-651.
4. Arosio D., Manzoni L., Araldi E.M.V., Scolastico C. Cyclic RGD functionalized gold nanoparticles for tumor targeting. Bioconjugate Chem 2011, 22:664-672.
5. 3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides. Curr Med Chem 2010, 17:1255-1299.
6. Barczyk M., Carracedo S., Gullberg D. Integrins. Cell Tissue Res 2010, 339:269-280.
7. Chen K., Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics 2011, 1:189-200.
8. Cox D., Brennan M., Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Disc 2010, 9:804-820.
9. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
10. Francischetti I.M.B. Platelet aggregation inhibitors from hematophagous animals. Toxicon 2010, 56:1130-1144.
11. Frank A.O., Otto E., Mas-Moruno C., Schiller H.B., Marinelli L., Cosconati S., et al. Conformational control of integrin-subtype selectivity in isoDGR peptide motifs: a biological switch. Angew Chem Int Ed Engl 2010, 49:9278-9281.
12. Hippenmeyer P.J., Ruminski P.G., Rico J.G., Lu H.S., Griggs D.W. Adenovirus inhibition by peptidomimetic integrin antagonists. Antiviral Res 2002, 55:169-178.
13. Huang J., Ding J. Nanostructured interfaces with RGD arrays to control cell-matrix interaction. Soft Matter 2010, 6:3395-3401.
14. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. J Cell Sci 2006, 119:3901-3903.
15. Jackson D.Y. Alpha 4 integrin antagonists. Curr Pharm Des 2002, 8:1229-1253.
16. Kerr J.R. Cell adhesion molecules in the pathogenesis of and host defence against microbial infection. Mol Pathol 1999, 52:220-230.
17. Kijimoto-Ochiai S., Noguchi A. Two peptides from CD23, including the inverse RGD sequence and its related peptide, interact with the MHC class II molecule. Biochem Biophys Res Commun 2000, 267:686-691.
18. Lee S., Xie J., Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev 2010, 110:3087-3111.
19. Mas-Moruno C., Rechenmacher F., Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010, 10:753-768.
20. Mhedbi-Hajri N., Jacques M.-A., Koebnik R. Adhesion mechanisms of plant-pathogenic Xanthomonadaceae. Bacterial adhesion 2011, 71-89. Springer, Dordrecht: The Netherlands. D. Linke, A. Goldman (Eds.).
21. Mousa S.A. Cell adhesion molecules: potential therapeutic and diagnostic implications. Mol Biotechnol 2007, 38:33-40.
22. Pasikowski P., Cydzik M., Kluczyk A., Stefanowicz P., Szewczuk Z. Ubiquitin fragments: their known biological activities and putative roles. BioMol Concepts 2010, 1:67-83.
23. Perdih A., Sollner Dolenc M. Small molecule antagonists of integrin receptors. Curr Med Chem 2010, 17:2371-2392.
24. Schwarz-Linek U., Höök M., Potts J.R. The molecular basis of fibronectin-mediated bacterial adherence to host cells. Mol Microbiol 2004, 52:631-641.
25. 3 integrins in the development of cancer therapy. Curr Cancer Drug Targets 2009, 9:519-540.
26. Siemion I.Z., Gawłowska M., Ślepokura K., Biernat M., Wieczorek Z. The mimetics of antiadhesive peptides as the inhibitors of Mycibacterium kansasii phagocytosis. Peptides 2005, 26:1543-1549.
27. Singh B., Su Y., Riesbeck K. Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol 2010, 78:545-560.
28. Swenson S., Ramu S., Markland F.S. Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des 2007, 13:2860-2871.
29. Szewczuk Z., Wilczynski A., Dyba M., Petry I., Siemion I.Z., Wieczorek Z. New conformationally restricted analog of the immunosuppressory mini-domain of HLA-DQ and its biological properties. Peptides 2000, 21:1849-1858.
30. Tegtmeyer N., Hartig R., Delahay R.M., Rohde M., Brandt S., Conradi J., et al. Small fibronectin-mimicking protein from bacteria induces cell spreading and focal adhesion formation. J Biol Chem 2010, 285:23515-23526.
31. Tugizov S.M., Berline J.W., Palefsky J.M. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 2003, 9:307-314.
32. Vyas S.P., Vaidya B. Targeted delivery of thrombolytic agents: role of integrin receptors. Expert Opin Drug Deliv 2009, 6:499-508.
33. Xie C., Zhu J., Chen X., Mi L., Nishida N., Springer T.A. Structure of an integrin with an αI domain, complement receptor type 4. EMBO J 2010, 29:666-679.
34. 3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296:151-155.
35. Zhou Y., Chakraborty S., Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics 2011, 1:58-82.